Three-dimensional extracellular matrix culture models of EGFR signalling and drug response

2007 ◽  
Vol 35 (4) ◽  
pp. 665-668 ◽  
Author(s):  
P.A. Kenny

Three-dimensional extracellular matrix culture, on substrata such as Matrigel, restores many aspects of the differentiated state to non-malignant cells from a variety of tissues. We have adapted these techniques to study EGFR (epidermal growth factor receptor) signalling and drug response in breast cancer cell lines. EGFR-dependent breast cancer cell lines undergo a striking reversion of the malignant phenotype upon treatment with inhibitors targeting the receptor, or downstream signalling intermediates such as mitogen-activated protein kinase and PI3K (phosphoinositide 3-kinase). Using this approach, we have recently reported that EGFR signalling in breast cancer can be effectively inhibited by blocking the activity of a key protease, TACE [TNFα (tumour necrosis factor α)-converting enzyme], which regulates the bioavailability of EGFR ligands. These results suggest a new way to target EGFR signalling in tumours of the breast and other epithelial tissues and underline the value of three-dimensional extracellular matrix culture models for exploring cancer-relevant signalling processes ex vivo.

2014 ◽  
Vol 8 (1) ◽  
pp. 75 ◽  
Author(s):  
Silvia der Heyde ◽  
Christian Bender ◽  
Frauke Henjes ◽  
Johanna Sonntag ◽  
Ulrike Korf ◽  
...  

2007 ◽  
Vol 1 (1) ◽  
pp. 84-96 ◽  
Author(s):  
Paraic A. Kenny ◽  
Genee Y. Lee ◽  
Connie A. Myers ◽  
Richard M. Neve ◽  
Jeremy R. Semeiks ◽  
...  

2020 ◽  
Vol 21 (12) ◽  
pp. 4413 ◽  
Author(s):  
Austin R. Holub ◽  
Anderson Huo ◽  
Kavil Patel ◽  
Vishal Thakore ◽  
Pranav Chhibber ◽  
...  

Traditionally, two-dimensional (2D) monolayer cell culture models have been used to study in vitro conditions for their ease of use, simplicity and low cost. However, recently, three-dimensional (3D) cell culture models have been heavily investigated as they provide better physiological relevance for studying various disease behaviors, cellular activity and pharmaceutical interactions. Typically, small-sized tumor spheroid models (100–500 μm) are used to study various biological and physicochemical activities. Larger, millimetric spheroid models are becoming more desirable for simulating native tumor microenvironments (TMEs). Here, we assess the use of ultra-large spheroid models (~2000 μm) generated from scaffolds made from a nozzle-free, ultra-high resolution printer; these models are explored for assessing chemotherapeutic responses with molecular doxorubicin (DOX) and two analogues of DoxilⓇ (Dox-NPⓇ, DoxovesTM) on MDA-MB-231 and MCF-7 breast cancer cell lines. To provide a comparative baseline, small spheroid models (~500 μm) were developed using a self-aggregation method of MCF-7 breast cancer cell lines, and underwent similar drug treatments. Analysis of both large and small MCF-7 spheroids revealed that Dox-NP tends to have the highest level of inhibition, followed by molecular doxorubicin and then Doxoves. The experimental advantages and drawbacks of using these types of ultra-large spheroids for cancer research are discussed.


PLoS ONE ◽  
2012 ◽  
Vol 7 (7) ◽  
pp. e40900 ◽  
Author(s):  
Kui Shen ◽  
Shara D. Rice ◽  
David A. Gingrich ◽  
Dakun Wang ◽  
Zhibao Mi ◽  
...  

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Yongxian Zhuang ◽  
Jordan M. Grainger ◽  
Peter T. Vedell ◽  
Jia Yu ◽  
Ann M. Moyer ◽  
...  

AbstractThe application of patient-derived xenografts (PDX) in drug screening and testing is a costly and time-consuming endeavor. While cell lines permit extensive mechanistic studies, many human breast cancer cell lines lack patient characteristics and clinical treatment information. Establishing cell lines that retain patient’s genetic and drug response information would enable greater drug screening and mechanistic studies. Therefore, we utilized breast cancer PDX from the Mayo Breast Cancer Genome Guided Therapy Study (BEAUTY) to establish two immortalized, genomically unique breast cancer cell lines. Through extensive genetic and therapeutic testing, the cell lines were found to retain the same clinical subtype, major somatic alterations, and drug response phenotypes as their corresponding PDX and patient tumor. Our findings demonstrate PDX can be utilized to develop immortalized breast cancer cell lines and provide a valuable tool for understanding the molecular mechanism of drug resistance and exploring novel treatment strategies.


Sign in / Sign up

Export Citation Format

Share Document